HOPITAL ROBERT SCHUMAN DE VANTOUX

The department of internal medicine at HOPITAL ROBERT SCHUMAN DE VANTOUX is conducting studies that target digestive cancer and locally advanced pancreatic cancer, aiming to improve surgical outcomes and extend patient survival.

• Flash dose of corticosteroids before curative‑intent digestive cancer surgery
• Maintenance therapy with OSE2101 plus FOLFIRI after FOLFIRINOX induction
• Evaluation of overall survival in metastatic pancreatic ductal adenocarcinoma

These trials seek to reduce postoperative complications and provide effective long‑term treatment options for patients undergoing cancer surgery or chemotherapy.

Research at the site includes a focus on Eosinophilic granulomatosis with polyangiitis (EGPA), exploring ways to lessen reliance on steroids while achieving disease remission.

• Glucocorticoid‑sparing effect of a mepolizumab‑based regimen
• Comparison with conventional therapeutic strategies for EGPA
• Assessment of prednisone dose reduction to 4 mg or less

The goal is to improve quality of life for newly diagnosed or relapsing EGPA patients by testing targeted biologic therapy.

Studies also examine key immune system processes that underlie treatment responses in both cancer and vasculitis, highlighting the role of immune modulation in patient care.

• Impact of preoperative corticosteroids on immune response after digestive cancer surgery
• Selection of HLA‑A2 positive patients for immunotherapy in pancreatic cancer
• Evaluation of mepolizumab’s effect on eosinophil‑driven inflammation in EGPA

By linking immune mechanisms to clinical outcomes, the trials aim to refine therapeutic strategies across multiple disease areas.